Developer docs
API playgroundTry for free, no card

Search company profiles

MuMac Ltd.

Full company profile

uuid002dw2a

Namestring
MuMac Ltd.
Legal namestring
MuMac Ltd.
Websiteurl
mumacltd.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

MuMac Ltd. is a UK-based medical device spin-out from the University of Manchester, founded by David Carden, Professor Ian Murray, and Dr. Jeremiah Kelly. The company commercializes patented dark adaptation measurement technology developed by its founders, and its core product, RapiDA, is a digital dark adaptometer designed for the early detection of Age-Related Macular Degeneration (AMD). RapiDA uses a dual-stimulus method (an arc-shaped green stimulus on a red background) to measure rod photoreceptor recovery in low lighting conditions, completing screening in approximately five minutes with clinical-trial-reported sensitivity of 19/20 and specificity of 18/20. The device is MHRA-approved as a medical device for research, supported by National Institute of Health Research (NIHR)-funded clinical trials, and is protected by US Patent 9,526,413.

The company pursues a direct-sales model targeting eye clinics, ophthalmology practices, and healthcare systems (principally the NHS in England), positioning RapiDA as a functional biomarker screening tool for busy clinical settings that can be operated by non-specialist staff. Pricing is not publicly disclosed and the company has no named reference customers in the available data. Revenue is generated through hardware sales of the RapiDA device. The company has signaled further product development in its pipeline and has appointed senior medtech commercial experience via Non-Executive Director Dr. Bill Pigg (formerly of Smith & Nephew, Johnson & Johnson, Systagenix, and Acelity). The firm is privately held by its founders with no disclosed external venture or institutional investors.

Within its addressable market, MuMac operates against a backdrop of significant demand: AMD affects roughly 30% of those over 65 in developed countries, with 3.65 million sufferers in the UK and 196 million cases globally, against a $7.8 billion AMD drug market growing at 7.8% annually. Mumac's commercialization remains early-stage, with MHRA clearance presently scoped to research, no disclosed revenue, and 1-10 employees reported.

Short descriptiontext

MuMac Ltd. is a University of Manchester spin-out that develops and sells RapiDA, a digital dark adaptometer medical device for early screening of Age-Related Macular Degeneration, targeting eye clinics and healthcare systems such as the NHS.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersManchester, United Kingdom
HQ citystring
Manchester
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic medical devices, dark adaptometry screening, AMD diagnostic instruments, clinical ophthalmology equipment, retinal health screening
Industry1 code
PRIMARYHLAHAJAC
Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Optical Instruments & Lenses3827
Product category
Ophthalmic Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1RapiDA Device Sales
TypeHardware Sales
Description

Sale of RapiDA digital dark adaptometer medical devices to eye clinics and healthcare providers for AMD screening.

mumacltd.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MuMac Ltd. develops and sells RapiDA, a digital dark adaptometer medical device that detects Age-Related Macular Degeneration (AMD) at the earliest possible stage by measuring how quickly the eye recovers sensitivity in dim lighting conditions. The five-minute screening test uses patented dark adaptation measurement technology with a dual stimulus method and real-time data analysis. The device is MHRA-approved for research, designed for use by non-specialist operators, and targets eye clinics, ophthalmology practices, and healthcare systems.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 19 of 20 AMD patients correctly identified (sensitivity)
+2 more records
Product overview1 text field

MuMac Ltd. is a University of Manchester spin-out company specializing in innovative ophthalmic instruments. The company's primary product is RapiDA, a digital dark adaptometer that detects Age-Related Macular Degeneration (AMD) at early stages through patented dark adaptation measurement technology. The core product portfolio includes RapiDA as the main commercial offering, alongside prior ophthalmic instruments developed by the founders such as the Macular Pigment Screener (MPS) and Ocular Stress Monitor. The company is developing other innovative products in its pipeline.

Product and service1 record
1RapiDA
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Optos manufactures ultra-widefield retinal imaging devices used for AMD and retinal disease screening in optometry and ophthalmology. It targets the same AMD detection workflow as RapiDA via a different (structural imaging) modality.

2Carl Zeiss Meditec
TypeBroad incumbent
Description

Carl Zeiss Meditec provides a broad ophthalmic diagnostic portfolio including OCT and retinal imaging used in AMD assessment. As a diversified incumbent with an installed base of imaging devices, it is the principal structural-imaging alternative to RapiDA in clinical practice.

TypeBroad incumbent
Description

Heidelberg Engineering is a leading manufacturer of OCT and confocal ophthalmic imaging systems widely used in AMD diagnosis. As a broad incumbent, it offers overlapping diagnostic capability but does not specialize in functional dark adaptation testing like RapiDA.

TypeDirect peer
Description

Konan Medical manufactures ophthalmic diagnostic devices including functional vision testing and electrophysiology instruments used in AMD and retinal disease workups. It competes with RapiDA for clinical ophthalmology slots focused on functional, not just structural, retinal assessment.

TypeDirect peer
Description

Reichert manufactures ophthalmic instruments including visual field analyzers and other functional vision testing devices used in eye clinics. It overlaps with RapiDA's functional vision testing positioning in the same ophthalmology channel.

TypeBroad incumbent
Description

Nidek produces ophthalmic diagnostic equipment including OCT and retinal imaging systems used in AMD and retinal disease clinics. It serves the same ophthalmology and optometry buyers as MuMac with a broader, primarily structural-imaging portfolio.

TypeDirect peer
Description

iCare, through its CenterVue acquisition, produces retinal imaging and perimetry devices used in ophthalmic diagnostics including AMD assessment. It serves the same ophthalmology customer base as MuMac with a portfolio of structural and functional vision devices.

TypeEmerging player
Description

Notal Vision developed ForeseeHome, a home-based preferential hyperacuity perimetry test for AMD monitoring. It is an emerging player in the same AMD-detection space but focused on home monitoring between clinic visits rather than in-clinic screening like RapiDA.

TypeBroad incumbent
Description

Topcon manufactures OCT, fundus cameras, and other ophthalmic diagnostic devices used by eye clinics globally. It overlaps with RapiDA's clinical customer base and represents the structural-diagnostic incumbent that RapiDA must position alongside or against.

TypeDirect peer
Description

MacuLogix developed the AdaptDx, a digital dark adaptometer for early AMD detection — the closest direct competitor to MuMac's RapiDA. Both devices use rod-recovery dark adaptation as a functional biomarker for early AMD, competing head-to-head for the same ophthalmology and optometry customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MuMac Ltd.

Ophthalmic Medical Devicesmumacltd.com

MuMac Ltd. is a University of Manchester spin-out that develops and sells RapiDA, a digital dark adaptometer medical device for early screening of Age-Related Macular Degeneration, targeting eye clinics and healthcare systems such as the NHS.

What MuMac Ltd. does

MuMac Ltd. is a UK-based medical device spin-out from the University of Manchester, founded by David Carden, Professor Ian Murray, and Dr. Jeremiah Kelly. The company commercializes patented dark adaptation measurement technology developed by its founders, and its core product, RapiDA, is a digital dark adaptometer designed for the early detection of Age-Related Macular Degeneration (AMD). RapiDA uses a dual-stimulus method (an arc-shaped green stimulus on a red background) to measure rod photoreceptor recovery in low lighting conditions, completing screening in approximately five minutes with clinical-trial-reported sensitivity of 19/20 and specificity of 18/20. The device is MHRA-approved as a medical device for research, supported by National Institute of Health Research (NIHR)-funded clinical trials, and is protected by US Patent 9,526,413.

The company pursues a direct-sales model targeting eye clinics, ophthalmology practices, and healthcare systems (principally the NHS in England), positioning RapiDA as a functional biomarker screening tool for busy clinical settings that can be operated by non-specialist staff. Pricing is not publicly disclosed and the company has no named reference customers in the available data. Revenue is generated through hardware sales of the RapiDA device. The company has signaled further product development in its pipeline and has appointed senior medtech commercial experience via Non-Executive Director Dr. Bill Pigg (formerly of Smith & Nephew, Johnson & Johnson, Systagenix, and Acelity). The firm is privately held by its founders with no disclosed external venture or institutional investors.

Within its addressable market, MuMac operates against a backdrop of significant demand: AMD affects roughly 30% of those over 65 in developed countries, with 3.65 million sufferers in the UK and 196 million cases globally, against a $7.8 billion AMD drug market growing at 7.8% annually. Mumac's commercialization remains early-stage, with MHRA clearance presently scoped to research, no disclosed revenue, and 1-10 employees reported.

MuMac Ltd. firmographics

Firmographics
Name
MuMac Ltd.
Legal name
MuMac Ltd.
Website
https://mumacltd.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
MuMac Ltd. is a University of Manchester spin-out that develops and sells RapiDA, a digital dark adaptometer medical device for early screening of Age-Related Macular Degeneration, targeting eye clinics and healthcare systems such as the NHS.
Ownership category
akta.pro rank

MuMac Ltd. industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAHAJAC
Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Ophthalmic medical devices
  • Dark adaptometry screening
  • AMD diagnostic instruments
  • Clinical ophthalmology equipment
  • Retinal health screening

Where MuMac Ltd. is headquartered

Location

Headquarters

HQ city
Manchester
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

MuMac Ltd. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. RapiDA Device Sales: Sale of RapiDA digital dark adaptometer medical devices to eye clinics and healthcare providers for AMD screening.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

MuMac Ltd. product offering

Product offering

Core offering

MuMac Ltd. develops and sells RapiDA, a digital dark adaptometer medical device that detects Age-Related Macular Degeneration (AMD) at the earliest possible stage by measuring how quickly the eye recovers sensitivity in dim lighting conditions. The five-minute screening test uses patented dark adaptation measurement technology with a dual stimulus method and real-time data analysis. The device is MHRA-approved for research, designed for use by non-specialist operators, and targets eye clinics, ophthalmology practices, and healthcare systems.

Product overview

MuMac Ltd. is a University of Manchester spin-out company specializing in innovative ophthalmic instruments. The company's primary product is RapiDA, a digital dark adaptometer that detects Age-Related Macular Degeneration (AMD) at early stages through patented dark adaptation measurement technology. The core product portfolio includes RapiDA as the main commercial offering, alongside prior ophthalmic instruments developed by the founders such as the Macular Pigment Screener (MPS) and Ocular Stress Monitor. The company is developing other innovative products in its pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • RapiDA

Quantifiable outcome

  • 19 of 20 AMD patients correctly identified (sensitivity)
  • +2 more outcomes

Companies that use MuMac Ltd.

Customer profile

Segments3 records

Ideal customer profiles2 records

MuMac Ltd. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

MuMac Ltd. partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

MuMac Ltd. competitors and assessment

Company assessment

Direct peers

  • Optos (Nikon): Optos manufactures ultra-widefield retinal imaging devices used for AMD and retinal disease screening in optometry and ophthalmology. It targets the same AMD detection workflow as RapiDA via a different (structural imaging) modality.
  • Konan Medical: Konan Medical manufactures ophthalmic diagnostic devices including functional vision testing and electrophysiology instruments used in AMD and retinal disease workups. It competes with RapiDA for clinical ophthalmology slots focused on functional, not just structural, retinal assessment.
  • Reichert Technologies: Reichert manufactures ophthalmic instruments including visual field analyzers and other functional vision testing devices used in eye clinics. It overlaps with RapiDA's functional vision testing positioning in the same ophthalmology channel.
  • iCare (CenterVue): iCare, through its CenterVue acquisition, produces retinal imaging and perimetry devices used in ophthalmic diagnostics including AMD assessment. It serves the same ophthalmology customer base as MuMac with a portfolio of structural and functional vision devices.
  • MacuLogix (AdaptDx): MacuLogix developed the AdaptDx, a digital dark adaptometer for early AMD detection — the closest direct competitor to MuMac's RapiDA. Both devices use rod-recovery dark adaptation as a functional biomarker for early AMD, competing head-to-head for the same ophthalmology and optometry customers.

Broad incumbents

  • Carl Zeiss Meditec: Carl Zeiss Meditec provides a broad ophthalmic diagnostic portfolio including OCT and retinal imaging used in AMD assessment. As a diversified incumbent with an installed base of imaging devices, it is the principal structural-imaging alternative to RapiDA in clinical practice.
  • Heidelberg Engineering: Heidelberg Engineering is a leading manufacturer of OCT and confocal ophthalmic imaging systems widely used in AMD diagnosis. As a broad incumbent, it offers overlapping diagnostic capability but does not specialize in functional dark adaptation testing like RapiDA.
  • Nidek: Nidek produces ophthalmic diagnostic equipment including OCT and retinal imaging systems used in AMD and retinal disease clinics. It serves the same ophthalmology and optometry buyers as MuMac with a broader, primarily structural-imaging portfolio.
  • Topcon Healthcare: Topcon manufactures OCT, fundus cameras, and other ophthalmic diagnostic devices used by eye clinics globally. It overlaps with RapiDA's clinical customer base and represents the structural-diagnostic incumbent that RapiDA must position alongside or against.

Emerging players

  • Notal Vision: Notal Vision developed ForeseeHome, a home-based preferential hyperacuity perimetry test for AMD monitoring. It is an emerging player in the same AMD-detection space but focused on home monitoring between clinic visits rather than in-clinic screening like RapiDA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

MuMac Ltd. social profiles

Digital presence

MuMac Ltd. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MuMac Ltd. leadership team

Management profile

Number of profiles

Profiles4 records

MuMac Ltd. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MuMac Ltd. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MuMac Ltd.

What does MuMac Ltd. do?

MuMac Ltd. develops and sells RapiDA, a digital dark adaptometer medical device that detects Age-Related Macular Degeneration (AMD) at the earliest possible stage by measuring how quickly the eye recovers sensitivity in dim lighting conditions. The five-minute screening test uses patented dark adaptation measurement technology with a dual stimulus method and real-time data analysis. The device is MHRA-approved for research, designed for use by non-specialist operators, and targets eye clinics, ophthalmology practices, and healthcare systems.

Is MuMac Ltd. a public or private company?

MuMac Ltd. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was MuMac Ltd. founded?

MuMac Ltd. was founded in 2019. It employs 1 to 10 people.

Where is MuMac Ltd. based?

MuMac Ltd. is headquartered in Manchester, United Kingdom, in the Europe region.

How does MuMac Ltd. make money?

One revenue line is on record: rapiDA Device Sales.

Who are MuMac Ltd.'s main competitors?

Direct peers on record are Optos (Nikon), Konan Medical, Reichert Technologies, iCare (CenterVue) and MacuLogix (AdaptDx). Broad incumbents are Carl Zeiss Meditec, Heidelberg Engineering, Nidek and Topcon Healthcare. Notal Vision is listed as an emerging player.

Does MuMac Ltd. have an API?

No public API is recorded for MuMac Ltd..

What industry is MuMac Ltd. in?

MuMac Ltd.'s product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAC, Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals